Reyataz 150 mg Hard Capsules

  • Name:

    Reyataz 150 mg Hard Capsules

  • Company:
    info
  • Active Ingredients:

    Atazanavir sulfate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/09/20

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 21/9/2020

Click on this link to Download PDF directly

Bristol-Myers Squibb Pharma EEIG

Company Products

Medicine NameActive Ingredients
Medicine Name Baraclude 0.05 mg/ml oral solution Active Ingredients Entecavir monohydrate
Medicine Name Baraclude 0.5 mg film coated tablets Active Ingredients Entecavir monohydrate
Medicine Name Baraclude 1.0 mg film coated tablets Active Ingredients Entecavir monohydrate
Medicine Name OPDIVO 10 mg/mL concentrate for solution for infusion Active Ingredients Nivolumab
Medicine Name ORENCIA 125 mg solution for injection in pre-filled pen Active Ingredients Abatacept
Medicine Name ORENCIA 250 mg powder for concentrate for solution for infusion Active Ingredients Abatacept
Medicine Name ORENCIA 50 mg, 87.5 mg and 125 mg solution for injection (pre-filled syringe) Active Ingredients Abatacept
Medicine Name Reyataz 150 mg Hard Capsules Active Ingredients Atazanavir sulfate
Medicine Name Reyataz 200 mg Hard Capsules Active Ingredients Atazanavir sulfate
Medicine Name Reyataz 300 mg Hard Capsules Active Ingredients Atazanavir sulfate
Medicine Name Sprycel 20mg, 50mg, 70mg and 100mg Film-Coated Tablets Active Ingredients dasatinib monohydrate
Medicine Name Sustiva 50 mg , 100 mg , 200 mg Hard Capsules Active Ingredients Efavirenz
Medicine Name Sustiva 600 mg Film-coated Tablets Active Ingredients Efavirenz
Medicine Name Yervoy 5mg per ml concentrate for solution for infusion Active Ingredients ipilimumab
1 - 0 of 14 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 September 2020 PIL

Reasons for updating

  • XPIL Updated

Updated on 21 September 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 21 September 2020

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

SmPC 4.3 and 4.5 - to add a new contraindication and a new drug-drug interaction related to co-administration with lomiptapide
SmPC 4.5 - to add a new drug-drug interaction related to co-administration with DOACs
SmPC 4.5 - to delete drug-drug interaction related to co-administration with boceprevir

Updated on 3 June 2020 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Update to Manufacturer: To add Swords Laboratories as an alternative site responsible for batch release. To change the name and amend the address of the site responsible for batch release from CATALENT Anagni

Updated on 3 June 2020

Reasons for updating

  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Date of revision of the text updated to align with the Patient Leaflet date of revision of the text - 01 April 2020

Updated on 25 February 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 22 February 2019

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The Marketing Authorisation Holder address has been changed.

Updated on 26 November 2018

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Updated on 10 October 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to date of revision

Updated on 10 October 2018

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

section 4.3 - amendment of text and addition of text 'Co-administration with glecaprevir/pibrentasvir fixed dose combination'

Section 4.5 - addtion of text related to co-administration of REYATAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated. Amendment of table related to interaction between reyataz and other medicinal products

Section 10 – updated date of revision

Updated on 25 May 2018

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Include information on the contraindicated co-administration with lurasidone

  • Section 4.3 Contraindactions
  • Section 4.5 Interaction with other medicinal products and other forms of interaction

Updated on 18 May 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications

Updated on 13 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 13 December 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 2 November 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 6 - date of revision

Updated on 8 September 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 4 January 2017 PIL

Reasons for updating

  • New individual PIL (was previously included in a combined PIL)